Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial

BACKGROUND: The clinical characteristics and treatment of patients who tested positive for COVID-19 after recovery remained elusive. Effective antiviral therapy is important for tackling these patients. We assessed the efficacy and safety of favipiravir for treating these patients. METHODS: This is...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Hong, Zhang, Chi, Zhu, Qi, Chen, Xianxiang, Chen, Guilin, Sun, Wenjin, Xiao, Zuohan, Du, Weijun, Yao, Jing, Li, Guojun, Ji, Yanhua, Li, Niuniu, Jiang, Yujin, Wang, Ying, Zeng, Qingjin, Li, Wei, Gong, Beilei, Chang, Xianyou, Zhu, Feng, Jiang, Xiufeng, Li, Jiawen, Wu, Zhao, Liu, Yingxia, Peng, Peng, Wang, Guiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059985/
https://www.ncbi.nlm.nih.gov/pubmed/33930706
http://dx.doi.org/10.1016/j.intimp.2021.107702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059985/
https://www.ncbi.nlm.nih.gov/pubmed/33930706
http://dx.doi.org/10.1016/j.intimp.2021.107702

Ejemplares similares